DocGo Inc.DCGO

DocGo Inc. spent the first quarter of 2026 watching nearly half of its Mobile Health Services revenue walk out the door, with the segment’s Q1 2026 take slipping to $23.6 million from $45.2 million a year earlier-a 47.8% drop that the company blames on the wind-down of migrant-related contracts and the absence of large temporary work. The headline figure is stark: overall revenues of $75.6 million, a net loss attributable to shareholders of $14.8 million, and an operating loss of $18.7 million for the three months ending 31 March 2026. (source: DCGO 10-Q, period ending 2026-03-31, https://www.sec.gov/Archives/edgar/data/1822359/000162828026033563/dcgo-20260331.htm)

What DocGo actually does is run a fleet of mobile health clinics and medical transport vans that roll up to patients, hospitals, and care homes across the United States, offering on-site diagnostics, phlebotomy, and non-emergency transport. The group bills itself as a technology-enabled provider of mobile health and medical transportation services, a description that sounds more sophisticated than the day-to-day reality of keeping ambulances fuelled and phlebotomists on rota. The core tension is straightforward: the business is trying to shift from episodic, high-volume crisis work to steadier, lower-margin routine care contracts, but the revenue bridge is still under construction while the cash burn continues. (source: DCGO 10-Q 2026-03-31, https://www.sec.gov/Archives/edgar/data/1822359/000162828026033563/dcgo-20260331.htm)

Cash generation is weak: net cash used in operating activities hit $4.7 million in the quarter, leaving $35.7 million in cash and cash equivalents on the balance sheet at 31 March 2026 against $98.0 million in liabilities. Research and development spend ticked up to $3.7 million, a rounding error compared to the operating losses, while capital expenditure was a modest $430,310. Diluted loss per share came in at $0.15 on 98.7 million diluted shares. The board, however, evidently sees enough optionality to extend the share-repurchase programme from 30 June 2026 to 31 December 2026, a move that looks less like confidence in the near-term cash engine and more like a bid to keep the share-price narrative alive while the fundamentals catch up. (source: DCGO 10-Q 2026-03-31 and DCGO SEC EDGAR 8-K 2026-07-02, https://www.sec.gov/Archives/edgar/data/1822359/000162828026033563/dcgo-20260331.htm and https://www.sec.gov/Archives/edgar/data/1822359/000162828026046919/dcgo-20260626.htm)

For readers hunting for live price feeds or intraday levels, the company’s shares trade under the ticker DCGO on the Nasdaq Capital Market; the official SEC filing index and company facts JSON can be pulled directly from the Commission’s EDGAR portal, but neither document contains chart data or valuation commentary. The market plumbing is standard Nasdaq, the liquidity is what it is, and the file stops at the numbers it supplies. (source: DCGO SEC EDGAR filing index, https://www.sec.gov/edgar/browse/?CIK=1822359; DCGO SEC companyfacts JSON, https://data.sec.gov/api/xbrl/companyfacts/CIK0001822359.json)

The business is now loudly touting two recent commercial launches: a longitudinal care partnership with a major California health plan and a mobile phlebotomy rollout in South Florida. Both press releases are crisp marketing copy, but they do not, on their own, restore the $21.6 million revenue gap that opened up in Mobile Health Services during Q1 2026. Until the routine-care contracts scale and the migrant-related work fully phases out, the gap between the van-side brand and the balance-sheet reality will remain the single biggest line item in the story. (source: DocGo press releases dated 2026-07-22 and 2026-07-08, https://docgo.com/press/docgo-announces-upcoming-launch-of-longitudinal-care-services-for-major-california-health-plan/ and https://docgo.com/press/docgo-launches-mobile-phlebotomy-services-in-south-florida/)

What the evidence does not contain is any segment-level profitability bridge, forward-looking cash-flow guidance, or a quantified path to covering the $18.7 million operating loss with the new routine-care contracts. The filings are transparent; the missing proof is not. Investors hunting for a clear operating bridge will need more than marketing releases and a buyback extension. (source: DCGO 10-Q 2026-03-31 and DCGO SEC EDGAR 2026-05-11, https://www.sec.gov/Archives/edgar/data/1822359/000162828026033563/dcgo-20260331.htm and https://www.sec.gov/Archives/edgar/data/1822359/00018235926000020/dcgo-20260511.htm)